Engineers Gate Manager LP Purchases 12,395 Shares of Natera, Inc. $NTRA

Engineers Gate Manager LP lifted its position in Natera, Inc. (NASDAQ:NTRA) by 43.6% in the second quarter, HoldingsChannel.com reports. The firm owned 40,839 shares of the medical research company’s stock after acquiring an additional 12,395 shares during the period. Engineers Gate Manager LP’s holdings in Natera were worth $11,086,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the company. Parallel Advisors LLC boosted its stake in Natera by 5.5% during the first quarter. Parallel Advisors LLC now owns 905 shares of the medical research company’s stock worth $181,000 after buying an additional 47 shares in the last quarter. Raiffeisen Bank International AG increased its holdings in Natera by 48.5% in the 2nd quarter. Raiffeisen Bank International AG now owns 150 shares of the medical research company’s stock valued at $41,000 after buying an additional 49 shares during the period. First Horizon Corp raised its stake in shares of Natera by 5.5% in the 1st quarter. First Horizon Corp now owns 982 shares of the medical research company’s stock valued at $196,000 after buying an additional 51 shares in the last quarter. Siemens Fonds Invest GmbH raised its stake in shares of Natera by 3.1% in the 3rd quarter. Siemens Fonds Invest GmbH now owns 1,804 shares of the medical research company’s stock valued at $290,000 after buying an additional 54 shares in the last quarter. Finally, Alamea Verwaltungs GmbH lifted its holdings in shares of Natera by 2.9% during the 4th quarter. Alamea Verwaltungs GmbH now owns 2,229 shares of the medical research company’s stock worth $515,000 after acquiring an additional 62 shares during the period. 99.90% of the stock is owned by institutional investors.

Analysts Set New Price Targets

Several analysts have recently weighed in on the stock. Weiss Ratings reiterated a “sell (d-)” rating on shares of Natera in a research report on Friday, July 17th. The Goldman Sachs Group began coverage on shares of Natera in a research report on Friday, June 5th. They issued a “neutral” rating and a $245.00 price target for the company. Leerink Partners set a $330.00 price target on shares of Natera in a research note on Friday, August 7th. Wells Fargo & Company lifted their price objective on Natera from $220.00 to $284.00 and gave the company an “equal weight” rating in a report on Friday, August 7th. Finally, Rothschild & Co Redburn started coverage on Natera in a report on Tuesday. They set a “buy” rating and a $385.00 price objective on the stock. Two investment analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating, four have issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, Natera has an average rating of “Moderate Buy” and an average price target of $330.83.

Natera Stock Performance

Shares of NASDAQ NTRA opened at $326.14 on Friday. The stock has a market cap of $47.01 billion, a PE ratio of -239.81 and a beta of 1.54. The business has a fifty day moving average of $296.81 and a two-hundred day moving average of $241.05. Natera, Inc. has a 52-week low of $157.43 and a 52-week high of $343.18.

Natera (NASDAQ:NTRA) last posted its earnings results on Thursday, August 6th. The medical research company reported ($0.47) earnings per share for the quarter, topping the consensus estimate of ($0.49) by $0.02. The business had revenue of $752.75 million for the quarter, compared to analyst estimates of $661.24 million. Natera had a negative net margin of 7.11% and a negative return on equity of 11.38%. The firm’s quarterly revenue was up 37.7% compared to the same quarter last year. During the same quarter in the prior year, the firm earned ($0.74) EPS. Analysts predict that Natera, Inc. will post -1.02 earnings per share for the current year.

Insider Transactions at Natera

In other Natera news, CEO Steven Chapman sold 3,580 shares of the company’s stock in a transaction dated Tuesday, July 28th. The shares were sold at an average price of $254.07, for a total transaction of $909,570.60. Following the sale, the chief executive officer directly owned 102,973 shares of the company’s stock, valued at approximately $26,162,350.11. This represents a 3.36% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director Herm Rosenman sold 16,530 shares of the firm’s stock in a transaction that occurred on Wednesday, June 24th. The stock was sold at an average price of $250.00, for a total transaction of $4,132,500.00. Following the sale, the director directly owned 4,250 shares of the company’s stock, valued at approximately $1,062,500. The trade was a 79.55% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders sold 71,206 shares of company stock valued at $19,944,069. 5.05% of the stock is owned by company insiders.

Natera Company Profile

Natera, Inc is a diagnostics company that develops and commercializes molecular testing services based on cell-free DNA and other genomic technologies. The company focuses on reproductive health, oncology and organ health, providing tests intended to support screening, diagnosis, treatment planning and disease monitoring.

Its reproductive health portfolio includes Panorama, a noninvasive prenatal test that screens for certain chromosomal conditions, and Horizon, a carrier screening test.